Vertex Faces Pain Drug Setbacks Amidst Q2 Earnings Beat
Vertex Pharmaceuticals' stock fell after its pain drug VX-993 failed a trial. Despite this, Q2 earnings exceeded estimates, driven by cystic fibrosis drugs. Journavx also faces FDA limitations.
/ 1 item
#VRTX↓